Estats Units - anglès - NLM (National Library of Medicine)

state of florida doh central pharmacy - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - for patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel tablets usp have been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (mi), or stroke as well as the rate of a combined endpoint of cardiovascular death, mi, stroke, or refractory ischemia. - for patients with st-elevation myocardial infarction (stemi), clopidogrel tablets usp have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. the benefit for patients who undergo primary percutaneous coronary intervention is unknown. the optimal duration of clopidogrel tablet usp therapy in acs is unknown. for patients with a history of recent myocardial infarction (mi), recent stroke, or established peripheral arterial disease, clopidogrel tablets usp ha

Estats Units - anglès - NLM (National Library of Medicine)

state of florida doh central pharmacy - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - for patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel tablets have been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (mi), or stroke as well as the rate of a combined endpoint of cardiovascular death, mi, stroke, or refractory ischemia. - for patients with st-elevation myocardial infarction (stemi), clopidogrel tablets have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. the benefit for patients who undergo primary percutaneous coronary intervention is unknown.  the optimal duration of clopidogrel tablet therapy in acs is unknown. for patients with a history of recent myocardial infarction (mi), recent stroke, or established peripheral arterial disease, clopidogrel tablets has been shown to

Estats Units - anglès - NLM (National Library of Medicine)

physicians total care, inc. - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - for patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel tablets have been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (mi), or stroke as well as the rate of a combined endpoint of cardiovascular death, mi, stroke, or refractory ischemia. - for patients with st-elevation myocardial infarction (stemi), clopidogrel tablets have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. the benefit for patients who undergo primary percutaneous coronary intervention is unknown.  the optimal duration of clopidogrel tablet therapy in acs is unknown. for patients with a history of recent myocardial infarction (mi), recent stroke, or established peripheral arterial disease, clopidogrel tablets has been shown to

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

clinect nz pty limited - clopidogrel bisulfate 98mg equivalent to 75 mg clopidogrel - tablet - 75 mg - active: clopidogrel bisulfate 98mg equivalent to 75 mg clopidogrel excipient: colloidal silicon dioxide crospovidone hyprolose hypromellose iron oxide red lactose macrogol 8000 methylcellulose purified water titanium dioxide zinc stearate - prevention of vascular ischaemia associated with atherothrombotic events (mi, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.

Canadà - anglès - Health Canada

teva canada limited - clopidogrel (clopidogrel bisulfate) - tablet - 300mg - clopidogrel (clopidogrel bisulfate) 300mg - platelet aggregation inhibitors

Canadà - anglès - Health Canada

apotex inc - clopidogrel (clopidogrel bisulfate) - tablet - 300mg - clopidogrel (clopidogrel bisulfate) 300mg - platelet aggregation inhibitors

Canadà - anglès - Health Canada

mint pharmaceuticals inc - clopidogrel (clopidogrel bisulfate) - tablet - 300mg - clopidogrel (clopidogrel bisulfate) 300mg - platelet aggregation inhibitors

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

multichem nz limited - clopidogrel besilate 112.1mg equivalent to clopidogrel 75 mg;  ;   - film coated tablet - 75 mg - active: clopidogrel besilate 112.1mg equivalent to clopidogrel 75 mg     excipient: citric acid monohydrate crospovidone hyprolose macrogol 6000 mannitol microcrystalline cellulose opadry pink 32k14834 purified talc stearic acid - prevention of vascular ischaemia associated with atherothrombotic events (mi, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; hyprolose; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red; microcrystalline cellulose - for prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. ,acute coronary syndrome: clopidogrel tablets is indicated in combination with aspirin for patients with: ,- unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel tablets is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularization (surgical or pci, with or without stent); ,- st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Estats Units - anglès - NLM (National Library of Medicine)

zydus lifesciences limited - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - clopidogrel tablet is indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non-st-segment elevation acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel tablets should be administered in conjunction with aspirin. - clopidogrel tablet is indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopidogrel tablets should be administered in conjunction with aspirin.  in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel tablet is indicated to reduce the rate of mi and stroke. clopidogrel bisulfate is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracran